AstraZeneca (AZN)
74.81
1.23 (1.67%)
At close: Feb 18, 2025, 3:59 PM
74.99
0.24%
After-hours: Feb 18, 2025, 07:05 PM EST
undefined% (undefined)
| Bid | 74.8 |
| Market Cap | 232.00B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 2.25 |
| PE Ratio (ttm) | 33.25 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 75 |
| Volume | 5,200,877 |
| Avg. Volume (20D) | 5,383,911 |
| Open | 74.24 |
| Previous Close | 73.58 |
| Day's Range | 74.22 - 74.97 |
| 52-Week Range | 62.75 - 87.68 |
| Beta | undefined |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardi...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date May 12, 1993
Employees 89,900
Stock Exchange NASDAQ
Ticker Symbol AZN
Website https://www.astrazeneca.com
Analyst Forecast
According to 7 analyst ratings, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $90, which is an increase of 20.30% from the latest price.
Buy 85.71%
Hold 14.29%
Sell 0.00%
Next Earnings Release
AstraZeneca is scheduled to release its earnings on Apr 24, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+2%
AstraZeneca shares are trading higher after the co...
Unlock content with
Pro Subscription
3 months ago
-7.22%
AstraZeneca shares are trading lower following a report suggesting that the company's insurance fraud involved senior executives in China.
